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Introduction. Prevalence of obesity and associated
diseases, including type 2 diabetes mellitus, dys-
lipidaemia and non-alcoholic fatty liver disease
(NAFLD), are increasing. Underlying mechanisms,
especially in humans, are unclear. Bariatric sur-
gery provides the unique opportunity to obtain
biopsies and portal vein blood-samples.
Methods. The BARIA Study aims to assess how
microbiota and their metabolites affect transcrip-
tion in key tissues and clinical outcome in obese
subjects and how baseline anthropometric and
metabolic characteristics determine weight loss
and glucose homeostasis after bariatric surgery.
We phenotype patients undergoing bariatric sur-
gery (predominantly laparoscopic Roux-en-Y gas-
tric bypass), before weight loss, with biometrics,
dietary and psychological questionnaires, mixed
meal test (MMT) and collect fecal-samples and
intra-operative biopsies from liver, adipose tissues
and jejunum. We aim to include 1500 patients. A
subset (approximately 25%) will undergo intra-
operative portal vein blood-sampling. Fecal-sam-
ples are analyzed with shotgun metagenomics and
targeted metabolomics, fasted and postprandial
plasma-samples are subjected to metabolomics,
and RNA is extracted from the tissues for RNAseq-
analyses. Data will be integrated using state-of-
the-art neuronal networks and metabolic model-
ing. Patient follow-up will be ten years.
Results. Preoperative MMT of 170 patients were
analysed and clear differences were observed in
glucose homeostasis between individuals.
Repeated MMT in 10 patients showed satisfactory
intra-individual reproducibility, with differences in
plasma glucose, insulin and triglycerides within
20% of the mean difference.
Conclusion. The BARIA study can add more under-
standing in how gut-microbiota affect metabo-
lism, especially with regard to obesity, glucose
metabolism and NAFLD. Identification of key
factors may provide diagnostic and therapeutic
leads to control the obesity-associated disease
epidemic.†Equal contribution.
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Introduction
Obesity is on the rise. At the current pace, more
than one billion adults will be obese by 2030 [1]. An
increase in obesity-associated diseases will follow
in its wake, including type 2 diabetes mellitus
(T2DM), dyslipidaemia, non-alcoholic fatty liver
disease (NAFLD) and cardiovascular disease. How-
ever, it has been challenging to identify underlying
molecular mechanisms contributing to car-
diometabolic diseases, in part because T2DM has
several subclasses [2]. Several pathways have been
suggested to contribute to obesity and impaired
glucose control, such as the immune system and
gut microbiota [3–5]. They include short-chain
fatty acids, bile acids, amino acids-derived metabo-
lites, neural pathways and lymphoid cells. Inter-
estingly, these have also been shown to be involved
in glucose metabolism and the development of
NAFLD, which illustrates the interconnectivity of
cardiometabolic diseases. Moreover, a chronic low-
grade inflammation can be measured in individu-
als with obesity, possibly caused by a disturbance
in the intestinal microbiota composition. Faecal
microbiota transplantation (FMT) from human
subjects to mice transferred adiposity phenotype
suggesting that, in mice, the microbiota may be a
contributing factor [6]. In humans, the effect of
FMT is less significant, yet insulin sensitivity can
improve for a short whilst in individuals with
metabolic syndrome after infusion of intestinal
microbiota from lean donors [7].
The relative contribution of different organs (liver,
adipose tissue and gut) to whole body metabolism
as well as immunological tone on weight loss in
relation to improvement of insulin sensitivity is not
known. Neither are the mechanisms that trigger
the innate and adaptive (intestinal) immune sys-
tem by altered intestinal microbiota, or their effects
on metabolism.
Most interventions aimed at losing weight in indi-
viduals with morbid obesity have little effect, except
for bariatric surgery [8]. Bariatric surgery is also the
most effective intervention to reduce obesity-related
morbidity andmortality [9]. In this regard, one of the
most common and well-studied bariatric proce-
dures is laparoscopic Roux-en-Y gastric bypass
(LRYGB). The increased insulin sensitivity found
shortly after LRYGB, even before significant weight
loss is obtained, suggests immediate systemic
changes in metabolism upon surgery, which are
long standing, as even ten years after surgery
beneficial effects on glucose metabolism, lipids and
blood pressure can be seen [10, 11].
Although being an important treatment for over
forty years, the mechanisms behind the beneficial
effect of bariatric surgery have been elusive. They
may include bile flow alteration, reduction of
gastric size, anatomical rearrangement and altered
flow of nutrients, vagal manipulation and enteric
gut hormone modulation [12]. Although some
studies have demonstrated that intestinal micro-
biota are altered after bariatric surgery as well, the
prospective value of (baseline) intestinal microbiota
composition and the relation with the (diet derived)
metabolites that these bacteria produce has never
been investigated at a larger scale [13, 14].
Significant differences in the response to bariatric
surgery can be observed, both in weight loss,
obesity-related morbidities and psychological fac-
tors, including self-esteem, risk of addiction and
quality of life [15–18]. Despite some methodological
limitations, psychological studies have shown
improvements in psychopathology, eating disor-
ders, depressive symptoms, body image and social
functioning after bariatric surgery [19]. Systems
biology models can provide an advanced recon-
struction of individuals’ metabolism at different
organ levels in patients with morbid obesity. They
could provide a valuable tool in predicting individ-
uals’ outcomes of bariatric surgery and hereby
develop a personalized medicine approach for this
disease. First steps in utilizing this technique to
study altered metabolism in obesity-related dis-
eases have produced interesting results [20–23].
We aim to perform a systems biology approach, as
schematically depicted in Fig. 1, identifying gut
microbial, immunological andmetabolicmarkers in
a large andwell phenotyped bariatric surgery cohort
(BARIA study) to identify signalling pathways that
can affect metabolic circuits in humans. Our study
aims to identify novel pathways in the pathogenesis
of obesity, T2DM and NAFLD, taking the gut–brain
axis into account as well, which may be targets for
drug development. Finally, we will follow the
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patients prospectively in an attempt to identify
mechanisms affecting the surgical outcome.
Methods
Study design
We include subjects that are patients with morbid
obesity scheduled for bariatric surgery. From
September 2016 until the end of 2018, the study
was performed at the former MC Slotervaart (Ams-
terdam) and is now continued, after closure of that
hospital, by the same surgical group and research
team at the Spaarne Gasthuis hospital (Hoofddorp)
in the Netherlands. The study protocols were
approved by the Ethical Review Board of the Aca-
demic Medical Center, Amsterdam, (approval code:
NL55755.018.15), and all patients that have been
(and will be) included provided informed consent.
Preoperative screening, surgery and follow-up are
performed following institutional procedure proto-
cols. All patients are screened preoperatively by a
bariatric surgeon, an internist, a dietician and a
psychologist. We aim to include predominantly
LRYGB procedures. In a shared decision-making
process, surgeon and patient decide for the bariatric
procedure type: LRYGB, laparoscopic omega-loop
gastric bypass (LOGB) or laparoscopic sleeve gas-
trectomy (LSG), which, in our bariatric surgery
centre, has resulted in more than 90% LRYGB of all
surgeries in thepast tenyears.All LRYGBprocedures
are standardized, with approximatedmeasurements
of 4 9 8 cm gastric pouch, 50 cm biliopancreatic
limb,150cmalimentary limb[24]. TheLOGBismade
with a longer gastric pouch and a longer biliopancre-
atic limb of approximately 200 cm. The LSG is
calibrated with a 34 Charriere bougie with the staple
line starting at approximately 2 cm from the pylorus.
Study population
Patients are screened at the outpatient clinic (MC
Slotervaart hospital, Spaarne Gasthuis hospital)
after being approved for bariatric surgery. Screening
started in September 2016. We aim to include 1500
Fig. 1 A systems biology approach, identifying gut microbial, immunological and metabolic markers in a large and well-
phenotyped bariatric surgery cohort: the BARIA study.
BARIA longitudinal cohort study / C. C. Van Olden et al.
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patients. Subjects are considered eligible for partic-
ipation if they meet following criteria:
Inclusion
• Male and female patients scheduled for primary
bariatric surgery recruited from an experienced
Dutch bariatric surgery clinic.
• Body mass index (BMI) ≥40 kg m2, or: BMI
≥35 kg m2 with obesity-related comorbidity.
• Recent history of supervised attempts to lose
weight.
• Age 18 to 65 years.
• Ability to provide informed consent.
Exclusion
• Primary lipid disorder.
• Known genetic basis for insulin resistance or
glucose intolerance.
• Psychiatric conditions.
• Coagulation disorders (patient reported or pro-
longed prothrombin time or activated partial
thromboplastin time).
• Uncontrolled hypertension (blood pressure
>150/95 mmHg).
• Renal insufficiency (creatinine >150 lmol L1).




For the characterization of subjects before surgery,
we have chosen variables that are linked to obesity
and obesity-associated diseases. For clinical fol-
low-up, we chose variables that can be tested
minimally invasive (only venepuncture) and which
can be easily reproduced, at low cost, without
extensive training in a Western hospital. The
reason for this is twofold. First, we aimed to
minimize the demand of our study subjects.
Secondly, our results need to be reproducible and
applicable in other settings without the need for
major investments in equipment or logistics. That
way our project can benefit the greatest number of
people whilst still remain ambitious in aiming to
discover new mechanisms.
The included patients undergo the repetitive mea-
surements detailed in Table 1. For the physicians
and researchers, we made a standard operating
procedure. The psychological measures were
assessed with Dutch versions of validated ques-
tionnaires, presented in Table 2. Tissue biopsies
are obtained during operation of three adipose
tissue compartments: subcutaneous (from one of
the laparoscopic incisions in the upper abdomen),
greater omentum and visceral fat (omental appen-
dices of the transverse colon); from the diaphrag-
matic surface of segment three or five of the liver;
and from the jejunum at the site of the jejunoje-
junostomy, approximately 50 cm from the Treitz
ligament. The jejunum biopsy cannot be obtained
during LOGB or LSG, as those operation tech-
niques, unlike LRYGB, do not involve a jejunoje-
junostomy. Blood sample of the portal vein is taken
at the beginning of the surgery, only if considered
safe by the surgeon, mainly depending on the
amount of fatty tissue surrounding the hepatoduo-
denal ligament. Biopsies are assessed for histology
(paraffin embedded), gene regulation (RNA-se-
quencing) and protein expression (immunoblot-
ting). NAFLD status is determined in histology of
liver biopsies and individually scored by members
of Dutch Liver Pathology Panel, after training
sessions, whilst difficult or borderline cases are
discussed during panel meetings for consensus.
SAF scores are determined, separately assessing
steatosis (S), activity (A, the sum of hepatocyte
ballooning and lobular inflammation), and fibrosis
(F) [25]. From the beginning of 2019, we added
routine preoperative ultrasound of the gallbladder.
Hollow needle subcutaneous fat aspirate biopsy
under local anaesthesia (peri-umbilical region) is
optional at follow-up. Of note, the tissues collected
during surgery comprise tissue that is thought to
play a crucial role in glucose metabolism and can
be biopsied with minimal risk to the patient being
small intestine, adipose tissue and liver samples.
We assess all liver biopsies for NAFLD/NASH, as it
is the gold standard for diagnosing liver disease.
Plasma metabolites are studied in portal vein blood
(fasted) and in both fasted and two hours after
mixed meal test (MMT) peripheral blood samples.
Intestinal immunological cells are looked for in
GALT tissue (Peyer’s patches), visceral and subcu-
taneous adipose tissue, liver in relation to inflam-
mation gene expression (IL -1b, IL-6, IL-8, IL-18,
CXCR2 TNF-a and TLR 1, 2, 4, 5 and 6 and IRX 3
and 5 and RNA-sequencing) and in specific innate
lymphoid cells (ILC), macrophages, T/B-cells and
dendritic cells and peripheral blood. Immunologi-
cal parameters assessed in small-intestinal tissue
and adipose tissue were selected for those that are
linked in literature to have an effect on glucose
metabolism and with which we have experience in
the analysis. Morning faecal samples obtained at
several time points will be analysed by shotgun
BARIA longitudinal cohort study / C. C. Van Olden et al.
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Table 1. Overview of visits and measurements. BARIA longitudinal cohort study
Visit Type of measurement Specific values







Demographic Age, sex, medical history, medication use,
history of obesity, history of smoking and
alcohol, education level, employment status,
anticonception use, physical activity
Biometric height, weight, waist and hip circumference,
temperature, blood pressure, pulse, non-
invasive haemodynamics (stroke volume,
cardiac output, systemic vascular
resistance), bioelectrical impedance
measurement, electrocardiogram
Blood Haemoglobin, CRP, leucocytes, platelets,
HbA1c, glucose, electrolytes, kidney function,
lipid profile, iron, hepatic enzymes, thyroid
profile, plasma metabolites
Stored plasma and DNA
samples (80°c)
Mixed meal test Glucose, insulin, triglycerides Stored plasma samples
(80°c)
Dietary questionnaire Satiety (visual analogue scale)[42], dietary
intake last 3 days prior to 24 h faeces
collection
Psychological questionnaire See Table 2.
Morning faecal samples
24 h faeces
Gut microbiota composition and faecal
metabolites (scfa), bile acids and caloric
bomb
Stored samples (80°c)
Gingival swab Oral microbiota Stored samples (80°c)








Snap frozen (liquid N2) and formaldehyde Stored samples (80°c) and
paraffin
Visceral adipose tissue Snap frozen (liquid N2) and formaldehyde Stored samples (80°c) and
paraffin
Omental adipose tissue Snap frozen (liquid N2) and formaldehyde Stored samples (80°c) and
paraffin




Snap frozen (liquid N2) and formaldehyde Stored samples (80°c) and
paraffin
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sequencing (NovaSeq). Buffycoat samples of
peripheral blood are taken at baseline for genomic
DNA analyses. Cardiac output and peripheral
resistance are assessed using the Nexfin system,
measuring blood pressure beat-to-beat with a
small cuff around the index finger [26].
In the case of a non-acute operation more than one
month after primary surgery, for example for
laparoscopic cholecystectomy, new liver and adi-
pose tissue biopsies can be obtained, as well as
gallbladder and bile from cholecystectomy
patients. Gallbladder tissue will be assessed for
bile acid composition, histology, gene expression
(RNA-sequencing) and protein expression.
The two-hour seven-sample oral MMT, as
described by Dalla Man et al., is repeated several
times over 2 years follow-up [27]. It consists of two
Nutridrink compact 125 mL (Nutricia), contain-
ing 23.3 grams fat, 74.3 grams carbohydrates (of
which 38.5 grams sugar) and 24.0 grams protein.
The patients receive this meal after fasting for a
minimum of nine hours. Time point zero is the
moment the patient fully consumed the meal.
Blood samples are drawn via intravenous line at
baseline, 10, 20, 30, 60, 90 and 120 min and
analysed for insulin sensitivity / insulin resis-
tance, plasma metabolites and bile acids.
Data handling and analysis
Data are collected on data collecting forms and
entered after validation in a computer system for
subsequent tabulation and statistical analysis. All
research and medical data are kept strictly
confidential and registered under a unique study
code. Only the researchers that are involved in this
study are able to see the data and to identify a
participant. Study material will be stored for a
period of 20 years after study completion. Data
from the first approximately 100 patients are
analysed to check data quality and logistics (first
data-freeze). A first interim analysis will be per-
formed on data of the first approximately 300
patients, and the primary analysis will be per-
formed on data of 500 patients (second and third
data- freeze). We intend to continue inclusions till
1500 for additional analyses and validation of
primary findings. The data are analysed using a
range of different techniques, including being used
as input for metabolic modelling and for pheno-
typing the patients using machine learning algo-
rithms.
Study integrity, monitoring, safety
The BARIA study is conducted according to the
principles of the Declaration of Helsinki (October
2013) and in accordance with the Medical Research
Involving Human Subjects Act (WMO). All adverse
events reported by the patients or observed by the
investigator or staff will be recorded. All adverse
events will be followed until they have abated, or
until a stable situation has been reached. Depend-
ing on the event, follow-up may require additional
tests or medical procedures as indicated.
Validation of the mixed meal test
Next to the elaborate analysis of data focussing on
the aims of the BARIA study, we used the results of
Table 1 (Continued )
Visit Type of measurement Specific values




Biometric Weight, waist and hip circumference, blood
pressure and pulse
Blood Haemoglobin, CRP, leucocytes, platelets,
HbA1c, glucose, electrolytes, kidney function,







Morning faeces Gut microbiota composition and faecal
metabolites (scfa)
Stored samples (80°c)
Urine Albumin and creatinine, metabolites Stored samples (80°c)
*At 5 and 10 years, no mixed meal test will be performed.
BARIA longitudinal cohort study / C. C. Van Olden et al.
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the preoperative MMT of the patients included and
operated in the first two years of the study to
validate the reproducibility of the MMT-stimulated
postprandial glucose, triglycerides and insulin
curves. We therefore stratified these results by
classifications of glycaemic control as formulated
in the American Diabetes Association (ADA) criteria:
normoglycemia (fasting glucose (FG) <100 mg dL1;
<5.6 mmol L1), impaired FG (100–125 mg dL1;
5.6–6.9 mmol L1) and / or increased haemoglobin
A1c (5.7–6.4%; 39–47 mmol mol1) and diabetes
mellitus (FG ≥126 mg dL1; ≥7.0 mmol L1) [28]. Of
all measurements during MMT in these patients,
there were 2.1% missing values for glucose, 5.5%
for insulin and 1.8% for triglycerides. We repeated
the preoperative MMT after one week in ten ran-
domly selected patients. Of all repeat measure-
ments of those ten patients, there were 2.9%
missing values for glucose, 5.7% for insulin and
none for triglycerides. For validating the MMT,
imputation of predictive mean matching was per-
formed for all missing values.
Results
Inclusion of patients in the BARIA study began in
September 2016. During the first two years of the
BARIA study, portal vein sampling was performed in
32% of the surgeries. Types of procedure were 94%
LRYGB, 6% LOGB and no LSG. No serious adverse
events occurred. Baseline characteristics and MMT
results of the first 170 patients included in this two-
year period are presented in Table 3. MMT curves of
ten patients assigned to the category diabetes
mellitus were excluded because of insulin use.
Results of the preoperative MMT of the remaining
160 patients are presented in Fig. 2. Individuals
with different classifications of glycaemic control
showed markedly different profiles for MMT-stimu-
lated plasma insulin, glucose and triglycerides.
Triglycerides were clearly higher at baseline and
all following time points in patients with IFG, with or
without increased Hba1c. HOMA2-IR and HOMA2-
B values and correlations with postprandial glucose
and insulin curves are presented in Fig. 3. The
HOMA2-IR and HOMA2-B values showed a good
correlation with the AUC postprandial insulin, but
not with the AUC postprandial glucose.
Results of the ten patients that underwent
repeated (1-week interval) preoperative MMT are
presented in Fig. 4. We found a good coefficient of
variance (figure 4, blue lines) with a mean average
of difference between two MMT measurements of
6.3% for area under the curve (AUC) postprandial
glucose, 13.9% for AUC postprandial insulin and
7.4% for AUC postprandial triglycerides, whilst
most of the differences between the two measure-
ments were well within the 20% range of the
average mean difference underscoring reasonably
good intraindividual reproducibility.
Discussion
The BARIA cohort study will generate a large
phenomic database on the systems biology of
Table 2. Psychological questionnaires. BARIA longitudinal
cohort study
Questionnaire No
Sociodemographic information: place of birth
patient, father, mother; number of children;
marital status; education; occupation.
7
Quality of life (WHO HIV QOL) 2
Change in life 1
Professional support 5
Self-management after Bariatric surgery (BSSQ) 8
TFEQ- hunger scale 9
Center for epidemiology studies depression scale
revised (CES-D)
20
Impact of weight on quality of life (IWQOL-Lite) 31
Body image scale 10
De Jong-Gierveld loneliness scale 11
Social participation scale 3
SCI exercise self-efficacy 10
Stanford exercise behaviour 6
Weight efficacy lifestyle questionnaire (WEL-Q) 20
G-food craving questionnaire-trait (FCQ-T) 21
Quality of relationship and relationship ladder 2
Experience in close relationships scale (ECRR-
SF)
16
Social support (SSQSR) 12
Social support and diet 10
Social support and exercise 13
Personality NEO-FFI (neuroticism and
conscientiousness subscales)
12+12
Self-compassion scale short form 12
Rosenberg self-esteem questionnaire 10
Chronotype working day 8
Chronotype free day 8
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subjects with morbid obesity, both before and after
bariatric surgery. Advanced data science, includ-
ing application of machine learning and artificial
neural networks data analysis is used to select
microbiome-produced metabolites and identify
their receptors in target tissue. It will be the first
large bariatric cohort study to include portal vein
blood sampling in a considerable subset of patients
for untargeted metabolites, which, when also
studying peripheral metabolites, will enable to
study the gradient of metabolites filtered by the
liver. We aim to include 1500 patients undergoing
primary laparoscopic bariatric surgery (gastric
bypass or sleeve gastrectomy). Before surgery, they
are subjected to MMT, blood and faecal sampling,
and questionnaires, including psychology and VAS
lists taken at the start of the MMT in all patients at
all time-points to minimize variation. During
surgery, biopsies are obtained from three fat
depots, jejunum, liver and samples from portal
and peripheral venous blood. Thereafter, further
sampling (MMT, blood and faecal samples) is
performed. In the event of another surgery (revi-
sional surgery, cholecystectomy) further biopsies
can be obtained, which is included in the ethical
protocol. We process tissues for RNA-sequencing,
analyse intestinal microbiota and perform untar-
geted (postprandial) plasma metabolomics on both
fasting and postprandial (MMT) plasma samples.
These metabolites will be investigated further
in vitro and in vivo to determine causality and
identify receptors. After the primary analysis, the
generated database will also allow for additional
secondary analyses.
The bariatric patient scheduled for primary bar-
iatric surgery is an interesting model for several
reasons. All patients suffer from morbid obesity
and generally expect to undergo examinations,
measurements and interviews both prior to surgery
Table 3. Baseline characteristics and results of mixed meal test in 170 participants in the first two years of inclusion in the
BARIA longitudinal cohort study, stratified by glycaemic classification, as formulated in the American Diabetes Association
criteria: normoglycemic (Healthy), impaired fasting glucose (IFG), increased haemoglobin A1c (IHbA1c), combination of IFG
and IHbA1c (Comb) and type 2 diabetes mellitus (T2DM). Categorical variables are displayed as absolute numbers
(percentage), continuous variables as means (SD).
Healthy IFG IHbA1c Comb T2DM
n 57 21 19 26 47
Age (years) 41.4 (11.1) 46.8 (11.7) 44.6 (9.5) 49.2 (9.2) 49.5 (10.2)
Sex (female) 45 (78.9) 20 (95.2) 17 (89.5) 16 (61.5) 31 (66.0)
BMI 39.5 (3.9) 39.4 (3.1) 40.6 (7.1) 40.6 (3.6) 39.2 (4.5)
Hypertension 8 (14.0) 5 (23.8) 3 (15.8) 8 (30.8) 25 (53.2)
Systolic BP (mmHg) 129.5 (16.6) 130.6 (13.6) 134.2 (15.8) 133.2 (12.0) 132.1 (13.7)
Diastolic BP (mmHg) 80.1 (11.3) 80.5 (8.2) 78.1 (13.2) 84.0 (7.9) 82.6 (9.4)
Insulin use 10 (21.3)
Glucose (mmol L1) 5.1 (0.4) 5.9 (0.2) 5.2 (0.2) 6.1 (0.4) 7.4 (1.5)
Insulin (pmol L1) 84.8 (48.0) 89.4 (46.5) 79.2 (37.2) 111.2 (46.9) 180.2 (222.5)
HbA1c (%) 5.31 (0.23) 5.41 (0.19) 5.79 (0.09) 5.88 (0.17) 7.10 (1.14)
HOMA2 IR 1.60 (0.90) 1.71 (0.83) 1.48 (0.67) 2.14 (0.85) 2.44 (1.24)
HOMA2 Beta (%) 125.4 (50.9) 98.1 (37.2) 112.6 (33.9) 105.8 (38.7) 87.3 (37.2)
AUC glucose (mmol L1) 137.1 (109.5) 122.5 (85.9) 194.6 (112.9) 211.7 (105.0) 386.3 (193.7)
AUC insulin (mmol L1) 42.3 (30.4) 46.0 (29.4) 48.7 (21.4) 50.8 (20.8) 37.6 (31.5)
eGFR (MDRD mL min1 1.73 m2) 94.5 (18.0) 92.7 (19.8) 95.6 (21.7) 94.7 (19.7) 95.7 (17.6)
ASAT (U L1) 23.6 (4.9) 23.5 (6.5) 25.1 (5.5) 25.3 (4.9) 29.9 (14.0)
ALAT (U L1) 28.6 (13.4) 28.3 (14.7) 33.7 (18.5) 30.4 (10.1) 42.1 (25.8)
Cholesterol (mmol L1) 4.6 (1.0) 5.1 (1.2) 5.2 (1.0) 4.8 (1.1) 4.1 (0.9)
HDLc (mmol L1) 1.12 (0.29) 1.13 (0.23) 1.16 (0.16) 1.08 (0.29) 1.05 (0.23)
Triglycerides (mmol L1) 1.08 (0.44) 1.58 (0.91) 1.10 (0.42) 1.79 (1.17) 1.40 (0.62)
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and in follow-up. The laparoscopic procedures give
proper access to different adipose compartments,
as well as liver and intestine for biopsy and, if the
hepatoduodenal ligament is not too much
embedded in fatty tissue, to the portal vein for fine
needle blood sample as well. Any haemorrhages
can readily be detected and addressed surgically,
minimizing the expected adverse events. In the
Fig. 2 Glucose, insulin and triglycerides measurements during 2-hour 7-sample mixed meal test, stratified by glycaemic
classification, as formulated in the American Diabetes Association criteria: normoglycemic (Healthy), impaired fasting
glucose (IFG), increased haemoglobin A1c (IHbA1c), combination of IFG and IHbA1c (Comb) and type 2 diabetes mellitus
(T2DM). Values are presented as means with 95% confidence intervals. (a) glucose curves; (b) insulin curves; (c) triglycerides
curves.
BARIA longitudinal cohort study / C. C. Van Olden et al.
ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 9
Journal of Internal Medicine
hands of our surgical team, mortality of routine
LRYGB is low (0.03%) and two-year follow-up is
high (71%) [24]. During the first two years of
inclusion, portal vein sampling could be performed
safely in about one out of three cases. Other
studies with similar bariatric surgery cohorts with
invasive assessments showed that a majority of
patients remains interested in participating during
two years of follow-up [29]. Furthermore, up to
10% of bariatric surgery patients need additional
surgery within two years after primary procedure
(for example revision surgery or cholecystectomy),
which opens up the possibility for renewed biopsies
and blood sampling [30].
However, studying bariatric patients has some
limitations intrinsic to the surgical procedure.
Biopsies and portal vein blood are taken under
general anaesthesia and therefore potentially influ-
enced by anaesthesia medication. For example,
Fig. 3 Area under the curve (AUC) of insulin and glucose during mixed meal test and HOMA2 insulin resistance (IR) and
beta cell function (B), stratified by glycaemic classification, as formulated in the American Diabetes Association criteria:
normoglycemic (Healthy), impaired fasting glucose (IFG), increased haemoglobin A1c (IHbA1c), combination of IFG and
IHbA1c (Comb) and type 2 diabetes mellitus (T2DM). Points are individual values, solid line represents linear regression,
banded area is 95% confidence interval. (a) Glucose AUC and HOMA2 IR. (b) Glucose AUC and HOMA2 B (%). (c) Insulin AUC
and HOMA2 IR. (d) Insulin AUC and HOMA2 B. Correlation coefficient (R) and P-values calculated with Spearman’s rank
correlation test.
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these drugs will be found in portal vein plasma and
might accumulate in fatty tissues during surgery
and, most importantly, will be metabolized by the
liver. Furthermore, patients are routinely urged by
their bariatric surgeon to lose as much weight as
possible before the operation to reduce the surgical
risk. It can be expected that such forced weight loss
will influence metabolism, gene expression and gut
microbiota. Although no standardized diet is pre-
scribed, we nevertheless choose to exclude those
patients that lose more than 5% in six months (or
more than 3% in one month) prior to surgery.
Another limitation is the fact that many patients
using medication for obesity-related diseases will
need less or even no medication after bariatric
surgery, which might be a confounder for outcome
measurements.
In a separate analysis of the MMT results in a
subset of included patients, we showed that the
preoperative MMT has a good intraindividual
reproducibility, which makes it a better estimate
for glycaemic regulation than the oral glucose
tolerance test [31]. We also showed that the MMT
is able to represent the underlying metabolic
dysregulation well, evident in the different curves
and the steady state model assessment. The
differences observed in the curves correspond well
with the pathophysiology. First, impaired fasting
glucose (IFG) is consistent with hepatic insulin
Fig. 4 Reproducibility of mixed meal test (MMT). Bland Altman plots of MMT (repeated within 1 week) for glucose, insulin
and triglycerides. Blue line is mean of difference between measurements, red line is  1.96*SD of mean difference, and
green line is  20% of mean difference. (a) Glucose area under the curve (AUC) in mmol L1*time. (b) Glucose AUC per cent
change. (c) Insulin AUC in mmol L1*time. (d) Insulin AUC per cent change. (e) Triglycerides AUC in mmol L1*time. (f)
Triglycerides AUC per cent change.
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resistance as is evident, apart from the increased
glucose, by increased baseline insulin and a
decreased suppression of apo B production,
resulting in increased triglycerides. An initial
quick rise in glucose is followed by a steady
decline of both glucose and insulin, as peripheral
insulin resistance remains largely normal [32].
Second, the increased haemoglobin A1c (IHbA1c)
group corresponds with peripheral insulin resis-
tance, represented by a steady increase until the
2-hour time point of both glucose and insulin with
relatively normal triglyceride levels. Finally, the
group with a combination of IHbA1c and IFG
(Comb) and the T2DM group show both charac-
teristics, with the T2DM group reaching higher
glucose levels. The HOMA2-IR and HOMA2-B
values showed a good correlation with the AUC
postprandial insulin, but not with the AUC post-
prandial glucose, which reiterates the suggestion
that they are used best in combination with other
clinical parameters [33].
With regard to the use of the MMT in postoperative
follow-up, it must be noted that the anatomical
changes affecting gastric emptying and resorption
might impede the comparison of the MMT before
and after surgery. However, the MMT is biologically
a more relevant test than the glucose tolerance
test, as one is rarely solely exposed to glucose
without fat and proteins. Studies with a similar
follow-up using intravenous glucose tolerance test
and euglycaemic-hyperinsulinaemic clamp showed
an improvement in insulin sensitivity in all
patients, with least improvement for TDM2
patients [34, 35]. One other study assessing meal
response after a follow-up of more than one year
was cross-sectional, but with smaller numbers
[36]. Outcome of the MMT in our BARIA study
can provide further insight in the metabolic
response following a meal after bariatric surgery.
Another limitation of the MMT in bariatric patients
is that the test can provoke early dumping, a well-
known side effect of LRYGB and LOGB due to loss
of pyloric regulation, which makes a heavy caloric
MMT hard to endure for some patients in the first
years of their follow-up.
We believe that the different subclasses of T2D are
different paths of progression to the disease, with,
in some individuals, a simultaneous existence of
several pathways [2]. The underlying molecular
mechanisms that lead to these different trajectories
are probably different. Similarly, the reversibility
and the therapeutic intervention that has the
greatest effect on their progression may vary. To
the best of our knowledge, there are no successful
therapeutic modalities specifically aimed at target-
ing short-chain fatty acids (SCFAs), bile acids,
amino acid-derived metabolites, neural pathways
and lymphoid cells with the aim of improving
glucose metabolism. There have been several trials
using specific SCFA as supplements to improve
glucose metabolism and weight loss [37, 38]. The
effects of the intervention in these studies as well
as in faecal microbiota transplantation studies are
usually limited with only few showing great
improvement [7] where other groups found less
efficacy of donor FMT (but were also using different
FMT applications), but did observe the similar
relation between FMT efficacy and decreased faecal
microbiota diversity at baseline [39]. A better
understanding of which molecular mechanisms
need to be targeted in which patients will lead to
a better personalized treatment.
With the comprehensive systems approach of the
BARIA longitudinal cohort study, we aim to provide
more understanding in to how the (small) intestinal
microbiota affects our metabolism, especially with
regard to NAFLD and T2DM. Moreover, we aim to
identify leads that drive weight loss and psycho-
logical improvement upon surgery, thus identifying
the causal factors connecting beneficial changes in
metabolism, microbiota and immunological tone
that will be of value to find new diagnostic and
therapeutic leads to control the obesity-associated
disease epidemic.
Lessons learned so far
During our study, we encountered a few learning
points, which, we hope, future researches planning
similar research can benefit from and not run into
the same problems. We based the feasibility of our
protocol on previous studies detailing MMT after
RYGB surgery [40, 41]. In our study so far, a
relatively large number (38 out of 134 participants)
of participants exhibited adverse effects during the
MMT at the one year after bariatric surgery (nausea,
diarrhoea, dizziness and weakness). We suspect
these adverse effects to be related to dumping
syndrome. The symptoms were not of a severity that
we found a need for extra diagnostic tests. None of
the subjects experienced loss of consciousness, and
there was no need for extended stay in the hospital
beyond the normal testing time. Another valuable
learning point was related to subject follow-up. In
order to achieve a dropout rate of <20%, extensive
BARIA longitudinal cohort study / C. C. Van Olden et al.
12 ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
contact with participants had to be maintained.
Many participants needed to be contacted via tele-
phone several times, for reminders to schedule every
visit. The amount of manpower and time necessary
for that was greater than we anticipated.
At the 6-week and 6-month collection time-points,
we collect blood for fasting glucose measurement,
as well as anthropometric measurements and
changes in medication. Our initial aim was to also
collect blood at the 2-week time-point. During our
try-out phase, we discovered that having these
measurements was too demanding for our patients
during this initial recovery period at 2 weeks.
Nutrition questionnaires were also reported as
stressful by our patients, and we have chosen to
only include these in the large (1 and 2 year)
collection time-points.
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